Practical management of major blood loss

Anaesthesia

Volumn 70, Issue S1, 2015, Pages

  Gill, R ^a  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR; PROTHROMBIN COMPLEX CONCENTRATES;

ERYTHROCYTE TRANSFUSION; HEMORRHAGE; HUMAN; THROMBOCYTE TRANSFUSION;

BLOOD COAGULATION FACTORS; ERYTHROCYTE TRANSFUSION; HEMORRHAGE; HUMANS; PLATELET TRANSFUSION;

EID: 84925223933     PISSN: 00032409     EISSN: 13652044     Source Type: Journal    
DOI: 10.1111/ANAE.12915     Document Type: Article

References (47)

1. Hardy JF, de Moerloose P, Samama CM. Massive transfusion and coagulopathy: Pathophysiology and implications for clinical management. Canadian Journal of Anesthesia 2006; 53: S40-58.
2. Martinowitz U, Michaelson M. Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: A report by the Israeli Multidisciplinary rFVIIa Task Force. Journal of Thrombosis and Haemostasis 2005; 3: 640-8.
3. Theusinger OM, Spahn DR, Ganter MT. Transfusion in trauma: Why and how should we change our current practice? Current Opinion in Anaesthesiology 2009; 22: 305-12.
4. Johansson PI. Treatment of massively bleeding patients: Introducing real-time monitoring, transfusion packages and thrombelastography (TEG_). International Society of Blood Transfusion Science Series 2007; 2: 159-67.
5. Association of Anaesthetists of Great Britain and Ireland. Blood transfusion and the anaesthetist: Management of massive haemorrhage. Anaesthesia 2010; 65: 1153-61.
6. Goodnough LT, Levy JH, Murphy MF. Concepts of blood transfusion in adults. Lancet 2013; 381: 1845-54.
7. Carson JL, Kuriyan M. What should trigger a transfusion? Transfusion 2010; 50: 2073-5.
8. Hebert PC, Wells G, Blajchman MA. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. New England Journal of Medicine 1999; 340: 1056.
9. Carson JL, Terrin ML, Noveck H, et al. Liberal or restrictive transfusion in high-risk patients after hip surgery. New England Journal of Medicine 2011; 365: 2453-62.
10. Kozek-Langenecker SA, Afshari A. Management of severe perioperative bleeding: Guidelines from the European Society of Anaesthesiology. European Journal of Anaesthesisology 2013; 30: 270-382.
11. O’Shaughnessy DF, Atterbury C, Maggs PB, et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. British Journal of Haematology 2004; 126: 11-28.
12. Stinger HK, Spinella PC, Perkins JG, et al. The ratio of fibrinogen to red cells transfused affects survival in casualties receiving massive transfusions at an army combat support hospital. Journal of Trauma: Injury, Infection, and Critical Care 2008; 64: S79-85.
13. Spinella PC, Perkins JG, Grathwohl KW, et al. Effect of plasma and red blood cell transfusions on survival in patients with combat related traumatic injuries. Journal of Trauma: Injury, Infection, and Critical Care 2008; 64: S69-78.
14. Maegele M, Lefering R, Paffrath T, et al. Red blood cell to plasma ratios transfused during massive transfusion are associated with mortality in severe multiply injury: A retrospective analysis from the Trauma Registry of the Deutsche Gesellschaft fr Unfallchirurgie. Vox Sanguinis 2008; 95: 112-9.
15. Snyder CW, Weinberg JA, McGwin G Jr, et al. The relationship of blood product ratio to mortality: Survival benefit or survival bias? Journal of Trauma: Injury, Infection, and Critical Care 2009; 66: 358-64.
16. Magnotti LJ, Zarzaur BL, Fischer PE, et al. Improved survival after hemostatic resuscitation: Does the emperor have no clothes? Journal of Trauma: Injury, Infection, and Critical Care 2011; 70: 97-102.
17. Stanworth SJ, Brunskill SJ, Hyde CJ. Is fresh frozen plasma clinically effective? A systematic review of randomized controlled trials. British Journal of Haematology 2004; 126: 139-52.
18. Bissell MG. The use of fresh-frozen plasma in England: High levels of inappropriate use in adults and children. Yearbook of Pathology and Laboratory Medicine 2012; 2012: 332-3.
19. Chowdhury P, Saayman AG, Paulus U, Findlay GP, Collins PW. Efficacy of standard dose and 30 ml/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients. British Journal of Haematology 2004; 125: 69-73.
20. Brohi K. Trauma induced coagulopathy. Journal of the Royal Army Medical Corps 2009; 155: 320-2.
21. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): A randomised, placebo-controlled trial. Lancet 2010; 376: 23-32.
22. Fenger-Eriksen C, Tønnesen E, Ingerslev J, Sørensen B. Mechanisms of hydroxyethyl starch-induced dilutional coagulopathy. Journal of Thrombosis and Haemostasis 2009; 7: 1099-105.
23. Dickneite G, Pragst I, Joch C, Bergman GE. Animal model and clinical evidence indicating low thrombogenic potential of fibrinogen concentrate (Haemocomplettan P). Blood Coagulation and Fibrinolysis 2009; 20: 535-40.
24. De Luca G, Verdoia M, Cassetti E, Schaffer A. High fibrinogen level is an independent predictor of presence and extent of coronary artery disease among Italian population. Journal of Thrombosis and Thrombolysis 2011; 31: 458-63.
25. Lang T, Johanning K, Metzler H, et al. The effects of fibrinogen levels on thromboelastometric variables in the presence of thrombocytopenia. Anesthesia and Analgesia 2009; 108: 751-8.
26. Fenger-Eriksen C, Lindberg-Larsen M, Christensen AQ, Ingerslev J, Sørensen B. Fibrinogen concentrate substitution therapy in patients with massive haemorrhage and low plasma fibrinogen concentrations. British Journal of Anaesthesia 2008; 101: 769-73.
27. Spahn DR, Cerny V, Coats TJ, et al. Management of bleeding following major trauma: A European guideline. Critical Care 2007; 11: R17.
28. Ciavarella D, Reed RL, Counts RB, et al. Clotting factor levels and the risk of diffuse microvascular bleeding in the massively transfused patient. British Journal of Haematology 1987; 67: 365-8.
29. Charbit B, Mandelbrot L, Samain E, et al. The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage. Journal of Thrombosis and Haemostasis 2007; 5: 266-73.
30. Karlsson M, Ternstrom L, Hyllner M, Baghaei F, Nilsson S, Jeppsson A. Plasma fibrinogen level, bleeding, and transfusion after on-pump coronary artery bypass grafting surgery: A prospective observational study. Transfusion 2008; 48: 2152-8.
31. Ucar HI, Oc M, Tok M, et al. Preoperative fibrinogen levels as a predictor of postoperative bleeding after open heart surgery. Heart Surgery Forum 2007; 10: E392-6.
32. Gerlach R, Tolle F, Raabe A, Zimmermann M, Siegemund A, Seifert V. Increased risk for postoperative hemorrhage after intracranial surgery in patients with decreased factor XIII activity: Implications of a prospective study. Stroke 2002; 33: 1618-23.
33. Weinstock N, Ntefidou M. SSC International Collaborative Study to establish the first high fibrinogen plasma reference material for use with different fibrinogen assay techniques. Journal of Thrombosis and Haemostasis 2006; 4: 1825-7.
34. Mittermayr M, Streif W, Haas T, Fries D. Hemostatic changes after crystalloid or colloid fluid administration during major orthopedic surgery: The role of fibrinogen administration. Anesthesia and Analgesia 2007; 105: 905-17.
35. Carroll RC, Craft RM, Chavez JJ, Snider CC. Measurement of functional fibrinogen levels using the Thrombelastograph. Journal of Clinical Anesthesia 2008; 20: 186-90.
36. Kalina U, Stohr HA, Bickhard H, Knaub S. Rotational thromboelastography for monitoring of fibrinogen concentrate therapy in fibrinogen deficiency. Blood Coagulation and Fibrinolysis 2008; 19: 777-83.
37. Rahe-Meyer N, Pichlmaier M, Haverich A, et al. Bleeding management with fibrinogen concentrate targeting a highnormal plasma fibrinogen level: A pilot study. British Journal of Anaesthesia 2009; 102: 785-92.
38. Weinkove R, Rangarajan S. Fibrinogen concentrate for acquired hypofibrinogenaemic states. Transfusion Medicine 2008; 18: 151-7.
39. Karlsson M, Ternstrom L, Hyllner M, et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery. A prospective randomised pilot study. Thrombosis and Haemostasis 2009; 102: 137-44.
40. Rahe-Meyer N, Solomon C, Hanke A, Schmidt DS. Effects of fibrinogen concentrate as first-line therapy during major aortic replacement surgery: A randomized, placebo-controlled trial. Anesthesiology 2013; 118: 40-50.
41. Levy JH, Tanaka KA, Dietrich W. Perioperative hemostatic management of patients treated with vitamin K antagonists. Anesthesiology 2008; 109: 918-26.
42. Hanke AA, Joch C, Gorlinger K. Long-term safety and efficacy of a pasteurized nanofiltrated prothrombin complex concentrate (Beriplex P/N): A pharmacovigilance study. British Journal of Anaesthesia 2013; 110: 764-72.
43. Keeling D, Baglin T, Tait C, et al. Guidelines on oral anticoagulation with warfarin - fourth edition. British Journal of Haematology 2011; 154: 311-24.
44. Pabinger I, Brenner B, Kalina U, et al. Prothrombin complex concentrate (Beriplex _ P/N) for emergency anticoagulation reversal: A prospective multinational clinical trial. Journal of Thrombosis and Haemostasis 2008; 6: 622-31.
45. Schochl H, Nienaber U, Hofer G, et al. Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEM_)-guided administration of fibrinogen concentrate and prothrombin complex concentrate. Critical Care 2010; 14: R55.
46. Gorlinger K, Dirkmann D, Hanke AA, Kamler M. First-line therapy with coagulation factor concentrates combined with point-of-care coagulation testing is associated with decreased allogeneic blood transfusion in cardiovascular surgery: A retrospective, single-center cohort study. Anesthesiology 2011; 115: 1179-91.
47. Weber CF, Gorlinger K, Meininger D, Herrmann E. Point-of-care testing: A prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients. Anesthesiology 2012; 117: 531-47.